NicOx partners with Bausch & Lomb for its candidate glaucoma drug
A worldwide licensing deal has been made between NicOx, the French biotech business and Bausch & Lomb for the former's candidate glaucoma drug NCX 116.
A worldwide licensing deal has been made between NicOx, the French biotech business and Bausch & Lomb for the former's candidate glaucoma drug NCX 116.
B&L will also be able to consider development and marketing of other products containing NCX 116 under the terms of the agreement. Phase II trials have been completed and clinical trials in patients with glaucoma and ocular hypertension are underway.
ARxVision, Seeing AI, NaviLens announce partnership for headset programme
April 1st 2024The UK's Royal National Institute of Blind People is the global distributor of the headset and ARxVision is partnering with the National Federation of the Blind and Vision Australia to expand global accessibility
